EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 21 / No 12 (Décembre 2005) Med Sci (Paris), 21 12 (2005) 1045-1053 References
Free Access
Issue
Med Sci (Paris)
Volume 21, Number 12, Décembre 2005
Page(s) 1045 - 1053
Section M/S revues
DOI https://doi.org/10.1051/medsci/200521121045
Published online 15 December 2005
  1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37 : 1595–607. [Google Scholar]
  2. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxydant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 2002; 16 : 1348–60. [Google Scholar]
  3. Alberti KGMM, Zimmet PZ. For the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15 : 539–53. [Google Scholar]
  4. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report on the National cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285 : 2486–97. [Google Scholar]
  5. The European group for the study of insulin resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28 : 364–76. [Google Scholar]
  6. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350 : 2362–74. [Google Scholar]
  7. Tounian P, Aggoun Y, Dubern B, et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001; 358 : 1400–4. [Google Scholar]
  8. New guidelines for metabolic syndrome. Pharma Marketletter 2005; April 25 : 21. [Google Scholar]
  9. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland coronary prevention study. Circulation 2003; 108 : 414–9. [Google Scholar]
  10. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worlwide populations. Endocrinol Metab Clin North Am 2004; 33 : 351–75. [Google Scholar]
  11. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365 : 1415–28. [Google Scholar]
  12. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP (National cholesterol education program) metabolic syndrome. The French DESIR study. Diabetes Metab 2003; 29 : 526–32. [Google Scholar]
  13. Gamila S, Dallongeville J. Épidémiologie du syndrome métabolique en France. Med Nutr 2003; 39 : 89–94. [Google Scholar]
  14. Standl E. Aetiology and consequences of the metabolic syndrome. Eur Heart J 2005; 7 (suppl) : D10–13. [Google Scholar]
  15. Lau DCW, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol 2005; 288 : H2031–41. [Google Scholar]
  16. Pritchett AM, Foreyt JP, Mann DL. Treatment of the metabolic syndrome: the impact of lifestyle modification. Curr Atheros Rep 2005; 7 : 95–102. [Google Scholar]
  17. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003; 290 : 486–94. [Google Scholar]
  18. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334 : 574–9. [Google Scholar]
  19. Yki-Järvinen. Thiazolidinediones. N Engl J Med 2004; 351 : 1106–18. [Google Scholar]
  20. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and g. J Clin Invest 2004; 114 : 1564–76. [Google Scholar]
  21. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation 2005; 111 : 2525–31. [Google Scholar]
  22. Khan MA, St Peter JV, Xue JL. A prospective, randomised comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25 : 708–11. [Google Scholar]
  23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian simvastatin survival study (4S). Lancet 1994; 344 : 1383–9. [Google Scholar]
  24. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis 2003; 171 : 1–13. [Google Scholar]
  25. Bloomfield Rubins H, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341 : 410–8. [Google Scholar]
  26. Heart protection study collaborative group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361 : 2560–72. [Google Scholar]
  27. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA 2003; 289 : 2560–72. [Google Scholar]
  28. Effets of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the Hope study and Micro-Hope substudy. Lancet 2000; 355 : 253–9. [Google Scholar]
  29. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (Life): a randomised trial against atenolol. Lancet 2002; 359 : 1004–10. [Google Scholar]
  30. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54 : 991–9. [Google Scholar]
  31. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of Telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43 : 993–1002. [Google Scholar]
  32. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26 : 244–50. [Google Scholar]
  33. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator activated receptor d activates fat metabolism to prevent obesity. Cell 2003; 113 : 159–70. [Google Scholar]
  34. Metabolex PPAR modulator shows no weight gain or oedema. SCRIP 2005; 3043 : 23. [Google Scholar]
  35. Howlett AC, Breivogel CS, Childers SR, et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 : 345–58. [Google Scholar]
  36. Steffens S, Veillard NR, Arnaud C, et al. Low dose of oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 : 782–6. [Google Scholar]
  37. Fernandez JR, Allison DB. Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 2004; 4 : 430–5. [Google Scholar]
  38. Boyd ST, Fremming BA. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 2005; 39 : 684–90. [Google Scholar]
  39. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev 2005; 4 : 193–205. [Google Scholar]
  40. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003; 290 : 2292–300. [Google Scholar]
  41. Birjmohon RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45 : 185–97. [Google Scholar]
  42. Meyers CD, Kashyap ML. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 2005; 20 : 307–12. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.